120 related articles for article (PubMed ID: 22416835)
21. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.
Dunne A; O'Hara T; Devane J
Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257
[TBL] [Abstract][Full Text] [Related]
22. The serum level approach to individualization of drug dosage.
Koch-Weser J
Eur J Clin Pharmacol; 1975 Oct; 9(1):1-8. PubMed ID: 786685
[TBL] [Abstract][Full Text] [Related]
23. Dosing considerations in the pediatric patient.
Skaer TL
Clin Ther; 1991; 13(5):526-44; discussion 525. PubMed ID: 1799910
[TBL] [Abstract][Full Text] [Related]
24. [Principles of therapeutic drug monitoring].
Widmer N; Csajka C; Werner D; Grouzmann E; Decosterd LA; Eap CB; Biollaz J; Buclin T
Rev Med Suisse; 2008 Jul; 4(165):1644-8. PubMed ID: 18767290
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a low order drug-cell response surface for applications in personalized medicine.
Ding X; Liu W; Weiss A; Li Y; Wong I; Griffioen AW; van den Bergh H; Xu H; Nowak-Sliwinska P; Ho CM
Phys Biol; 2014 Nov; 11(6):065003. PubMed ID: 25427213
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
27. A challenging drug development process in the era of personalized medicine.
Jørgensen JT
Drug Discov Today; 2011 Oct; 16(19-20):891-7. PubMed ID: 21945860
[TBL] [Abstract][Full Text] [Related]
28. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.
Postma MJ; Boersma C; Vandijck D; Vegter S; Le HH; Annemans L
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):367-9. PubMed ID: 21831013
[No Abstract] [Full Text] [Related]
29. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
Jelliffe RW; Schumitzky A; Van Guilder M; Liu M; Hu L; Maire P; Gomis P; Barbaut X; Tahani B
Ther Drug Monit; 1993 Oct; 15(5):380-93. PubMed ID: 8249044
[TBL] [Abstract][Full Text] [Related]
30. An autoregressive linear mixed effects model for the analysis of unequally spaced longitudinal data with dose-modification.
Funatogawa I; Funatogawa T
Stat Med; 2012 Mar; 31(6):589-99. PubMed ID: 22170221
[TBL] [Abstract][Full Text] [Related]
31. [Model building in pharmacokinetics/Part V: Simulation of blood level curves following repetitive dosing and their experimental verification (author's transl)].
Hammer R; Bozler G; Heinzel G; Koss FW
Arzneimittelforschung; 1977; 27(4a):928-31. PubMed ID: 577860
[TBL] [Abstract][Full Text] [Related]
32. The mathematics of drug dose individualization should be built with random-effects linear models.
Diaz FJ; de Leon J
Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456
[No Abstract] [Full Text] [Related]
33. Estimation of drug dosage regimens with a pharmacokinetic slide rule.
Straughn AB; Cruze CA; Meyer MC
Am J Hosp Pharm; 1977 Feb; 34(2):197-200. PubMed ID: 842548
[TBL] [Abstract][Full Text] [Related]
34. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".
Holford NH; Buclin T
Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647
[No Abstract] [Full Text] [Related]
35. [Therapeutic drug monitoring with the help of serum concentration measurements. How are the analytic results distributed in a population?].
Skomedal T; Osnes JB; Johannessen SI; Lund PK; Aass H
Tidsskr Nor Laegeforen; 1993 Aug; 113(18):2242-6. PubMed ID: 8362387
[TBL] [Abstract][Full Text] [Related]
36. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
Foo LK; McGree J; Duffull S
Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
[TBL] [Abstract][Full Text] [Related]
37. Analysis of dose-response in flexible dose titration clinical studies.
Xu XS; Yuan M; Nandy P
Pharm Stat; 2012; 11(4):280-6. PubMed ID: 22407972
[TBL] [Abstract][Full Text] [Related]
38. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments.
Ogungbenro K; Aarons L
Pharm Stat; 2010; 9(4):255-68. PubMed ID: 19714737
[TBL] [Abstract][Full Text] [Related]
39. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
[TBL] [Abstract][Full Text] [Related]
40. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.
Mentré F; Gomeni R
J Biopharm Stat; 1995 Jul; 5(2):141-58. PubMed ID: 7581424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
